Icon Bioscience Announces Daniel Dale, M.D. Joined The Company As President & Chief Executive Officer
Sunnyvale, CA (April 7, 2014) – Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug delivery platform to develop unique intraocular eye-care therapeutics, today announced that Daniel Dale, MD joined the Company as President & Chief Executive Officer.
Icon Bioscience noted that Dr. Dale is an acknowledged healthcare executive with confirmed achievements. He runs both pharmaceutical and medical device companies. Additionally, Dr. Dale gains rich experience in successfully developing and commercializing drug delivery platforms, a particularly valuable asset with regard to Icon’s Verisome technology.
“We are delighted to have Daniel join our team,” said Vernon G. Wong, MD, Chairman and founder of Icon Bioscience and inventor of Verisome. “Daniel possesses a wealth of expertise in medical science, clinical and regulatory affairs, and in overseeing the advancement of healthcare companies through the product development phase to commercial operations, key elements in support of Icon’s exciting growth outlook.”
Daniel Dale commented, “Icon is on the threshold of an important new growth phase as is evident from the Company’s robust product pipeline with its lead product candidate in late-stage development.” He further noted, “I expect Icon’s Verisome technology to drive a transformational change in ophthalmic pharmaceuticals and am thrilled to have the opportunity to participate and contribute to that prospect.”
About Daniel Dale , MD
Previously, Dr. Dale served as President in biopharmaceutical company since 2005. Prior to this, Dr. Dale was Chef of Pharmaceutical Technologies, a drug delivery division of Pharmaceutical Technologies – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as a vice president, Drug Development at Med Source Corporation and in a variety of management positions at Elan Corporation. Dr. Dale gained a medical degree from the National University of Ireland, Galway (NUIG).
Daniel Dale is the recipient of two Ernst & Young Entrepreneur of the Year awards, first in 2005 and again in 2008, respectively. He was also featured in the inaugural 2008 Irish Life Science 100, an honor presented by the President of Ireland in conjunction the Irish Voice and Irish America Magazine. Additionally, in 2005, 2006, and 2011 Daniel was named one of the most inspiring people in the health sciences by PharmaVOICE 100.
About Icon Bioscience and Verisome®
Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® drug delivery technology. The technology encompasses a broad number of related, but distinct drug delivery systems capable of incorporating an extensive range of active agents, including small molecules, proteins and monoclonal antibodies. Moreover, this drug delivery platform is a highly advanced, yet elegantly formulated system for controlling the release of medication within the eye for up to a year through the administration of a single injection. The technology’s exceptional versatility can support products individually formulated to meet the particular clinical requirements of a given active agent targeting a specific ophthalmic disease. Icon is actively developing a broad portfolio of specialty pharmaceuticals targeting several ophthalmic indications, including macular edema, glaucoma, age-related macular degeneration and cataract surgery. For additional information visit the Icon website at www.iconbioscience.com